Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × derazantinib × Clear all

NCT05174650 2025-12-05

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT03230318 2023-12-19

FIDES-01

Phase 2 Completed

148 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Liver Neoplasms, Cholangiocarcinoma